XMLWordPrintableJSON

Details

    • Icon: Comment Comment
    • Resolution: Considered - No action required
    • Icon: High High
    • US Core (FHIR)
    • 6.1.0
    • Biomedical Research & Regulation
    • US Core Condition Codes
    • Hide

      Variance approved in Cross-Group Projects call March 14, 2024:

      Motion to approve with proviso these are revisited when the IGs move to the next version of US Core.

      Eric Haas/Saul Kravitz:14-0-0

      Show
      Variance approved in Cross-Group Projects call March 14, 2024: Motion to approve with proviso these are revisited when the IGs move to the next version of US Core. Eric Haas/Saul Kravitz:14-0-0

    Description

      The concepts in pharmaceutical approval are vastly different than clinical care which is the basis for US Core. The Pharmaceutical Quality Submissions to Food & Drug Administration (PQ/CMC) IG will continue to create profiles that will characterize the manufacture of drugs. There will be a continued conflict with the US Core and more exceptions to come. Would it be possible to change the realm for this IG to C1 Unclassified Realm or create a Non-clinical Realm?

      Attachments

        Activity

          People

            Unassigned Unassigned
            chn@module3solutions.com CatherineHosage Norman
            Catherine Hosage Norman, Scott Gordon, Smita Hastak
            Watchers:
            2 Start watching this issue

            Dates

              Created:
              Updated:
              Resolved: